Brokerages Set Altimmune, Inc. (NASDAQ:ALT) Target Price at $20.00

Shares of Altimmune, Inc. (NASDAQ:ALT) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $20.00.

Several research firms have recently weighed in on ALT. Evercore ISI upgraded Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. B. Riley reissued a “buy” rating and set a $20.00 price objective on shares of Altimmune in a report on Monday, August 12th. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a research report on Thursday, November 14th. Finally, UBS Group initiated coverage on Altimmune in a research report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price objective on the stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ALT. Larson Financial Group LLC acquired a new stake in Altimmune in the 3rd quarter valued at approximately $31,000. CANADA LIFE ASSURANCE Co bought a new stake in shares of Altimmune during the 1st quarter worth approximately $44,000. TFO Wealth Partners LLC bought a new position in shares of Altimmune in the 1st quarter valued at about $51,000. Horizon Wealth Management LLC acquired a new stake in Altimmune in the 2nd quarter valued at about $66,000. Finally, PFG Investments LLC bought a new position in shares of Altimmune during the 2nd quarter worth approximately $67,000. 78.05% of the stock is owned by institutional investors and hedge funds.

Altimmune Stock Up 7.8 %

NASDAQ:ALT opened at $8.05 on Monday. The firm has a market cap of $572.52 million, a price-to-earnings ratio of -5.19 and a beta of 0.09. Altimmune has a 12 month low of $2.48 and a 12 month high of $14.84. The company’s 50 day moving average is $7.06 and its 200-day moving average is $6.92.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. The company had revenue of $0.01 million during the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same quarter last year, the firm earned ($0.39) earnings per share. Research analysts predict that Altimmune will post -1.36 EPS for the current fiscal year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.